Pressmeddelande -
Senzime and ProHelia initiates collaboration to improve blood sugar measurement and diagnostic healthcare
Uppsala, June 3, 2014. Senzime AB (publ) today announces that a new phase was initiated in the clinical evaluation of the company's analytical instrument CliniSenz. The aim is to demonstrate the benefits of CliniSenz ability to monitor blood sugar levels automatically and continuously in patients with elevated fasting blood glucose during an oral glucose tolerance test. The evaluation is done in collaboration with ProHelia företagshälsa AB in Uppsala and is expected to be completed in the fall of 2014.
Senzime develops analytical instrument CliniSenz which automatically and continuously monitor blood sugar levels in patients online. The reliability and ease of use is already well documented. The phase of the study starting now is focused on demonstrating the benefits of continuous monitoring of blood sugar levels in patients at risk of developing diabetes. Today diabetes is diagnosed using single blood samples, while CliniSenz allows the caregiver to study the detailed process during a glucose load. This enables a more accurate diagnosis and also provides information that may benefit individuals to manage their lifestyle or disease. This instrument is developed for use in both the hospital environment and in community care (occupational, health centers, etc.).
"The need to continuously monitor blood sugar level is high, both in health care and to increase the awareness of, for example, individuals with diabetes and overweight on how food and drink can affect their health. The individual can see on screen how food intake affects blood sugar levels -which can be an important incentive to change lifestyle factors, "says Lena Söderström, CEO of Senzime AB.
"Type 2 diabetes is increasing, partly due to lifestyle factors. The disease has serious consequences for the individual and huge costs to society. Through continuous monitoring of blood sugar levels may treating physician reach an accurate diagnosis, while the patient is receiving increased awareness of how physical activity and food intake can affect health, "says Thorbjörn Johansson, occupational doctor at ProHelia företagshälsa AB.
For further information, please contact:
Lena Söderström, CEO Senzime AB
Tel: +46 708-16 39 12, e-post: lena.soderstrom@senzime.com
Thorbjörn Johansson, occupational doctor ProHelia Tel: +46 18-46 88 00
TO THE EDITORS
About Senzime
Senzime develops and sells analytical instruments and related disposable products that enable automated, continuous monitoring of vital substances including glucose (sugar), in biological fluids. Many modern medicines are produced in living cells that are nourished in a glucose solution. In order to ensure maximum productivity in manufacturing, glucose levels should be measured continuously. BioSenzTM is an analytical instrument that performs this task. Senzime's market leading partner, Applikon, has started the global launch of BioSenzTM. Continuous glucose monitoring can also be used by healthcare providers, to improve outcomes of complex surgical procedures and dialysis care. For these purposes, the company develops the instrument CliniSenzTM. The company's share is listed on Aktietorget since 2008. www.senzime.com
About ProHelia
We at ProHelia company health focuses on your and your employees' health. We provide occupational health services, with service in medical and work -related areas, to companies and organizations. The goal is to perform full service on matters relating to their health and safety. Our occupational characterized by a wide range of expertise and personal attention that we offer small and large companies a complete occupational health. We operate both inside at our reception, but even looking at you in your business. We are very flexible and we have great opportunities to plan our visits at times that suit you the customer. We help large and small businesses to build routines for preventative health care. ProHelia företagshälsa AB is a member of the industry association Sweden Företagshälsor. ProHelia företagshälsa AB has been approved by the Social Insurance Agency, a premium to health care. www.prohelia.se
Ämnen
- Hälso-, sjukvård
Kategorier
- diabetes and me
- diabetes and foods
- diabetes 2
- glucose monitoring devices
- diabetes and diet
- lifestyle
- occupational health
- occupational health and wellbeing
- glucose monitoring
- senzime
- prohelia
Om Senzime
Senzime utvecklar och säljer analysinstrument med tillhörande förbrukningsmaterial och tillbehör. Utrustningen möjliggör automatiserad och kontinuerlig mätning av viktiga ämnen, bland annat glukos (socker), i biologiska vätskor. Många moderna läkemedel tillverkas av levande celler som hämtar sin näring ur en glukoslösning. Glukosnivån bör mätas kontinuerligt för att säkerställa maximal produktivitet i tillverkningen och BioSenz är ett analysinstrument som löser denna uppgift. Instrumentet lanseras globalt av Applikon, Senzimes marknadsledande partner. Kontinuerlig glukosmätning behövs även inom sjukvården för att öka patientöverlevnaden vid komplicerade kirurgiska ingrepp samt för att förbättra dialysvården. För dessa ändamål utvecklar bolaget instrumentet CliniSenz. Bolagets aktie är sedan 2008 noterad på Aktietorget.
För mer information, se www.senzime.com eller vänligen kontakta:
Lena Söderström, VD
Tel. +46 (0)18 51 56 40
Mobil +46 (0)708 16 39 12
